Featured Publication Accessing Improved TB Medicines for Children Click here to download the full reportResearch Papers Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial Daily Dosing for Bedaquiline in Patients with Tuberculosis Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerationsFor the PressPress Contact:Thomas Lynchp | +1 646 616 8639e | thomas.lynch@tballiance.org View the Annual Report 2018
